Post Traumatic Stress Disorder (PTSD) Market Report and Forecast 2024-2032

Post Traumatic Stress Disorder (PTSD) Market Report and Forecast 2024-2032


Post Traumatic Stress Disorder (PTSD) Market Report and Forecast 2024-2032

Post Traumatic Stress Disorder (PTSD) Market Outlook

The post-traumatic stress disorder (PTSD) market size is expected to grow at a CAGR of 5.4% during the forecast period of 2024-2032 in the major markets, driven by increasing prevalence of post-traumatic stress disorder (PTSD), along with reducing stigma around mental health conditions.

Post Traumatic Stress Disorder (PTSD): Introduction

Post Traumatic Stress Disorder (PTSD) is a mental health condition triggered by experiencing or witnessing a terrifying event. Symptoms include flashbacks, nightmares, severe anxiety, and uncontrollable thoughts about the event. Individuals may also experience emotional numbness and avoidance of situations that remind them of the trauma. PTSD can impair daily functioning and relationships. Treatment often involves psychotherapy, medication, or a combination, aiming to improve symptoms, teach coping strategies, and restore normal functioning.

Key Trends in the Post Traumatic Stress Disorder (PTSD) Market

There's a growing recognition of PTSD beyond traditional contexts like military veterans, encompassing first responders, victims of abuse, and survivors of accidents or natural disasters. This broader understanding is leading to increased diagnosis rates and a higher demand for treatment services.

The market is seeing a shift towards integrated treatment models that combine psychotherapy, medication, and holistic approaches like mindfulness, yoga, and acupuncture. Personalized treatment plans are becoming more common, addressing the individual needs of patients.

Telehealth services, mobile apps, and online therapy platforms are becoming increasingly popular for providing accessible PTSD treatment, especially in remote or underserved areas. Digital platforms also facilitate continuous monitoring and support for individuals with PTSD.

There's a growing emphasis on early intervention and preventive measures in high-risk populations. Programs aimed at education, resilience training, and early trauma counselling are being implemented in various settings, from schools to the military.

The pharmaceutical aspect of the PTSD market is exploring beyond traditional antidepressants. Research into new drug classes and the potential therapeutic use of substances like MDMA and psilocybin for treatment-resistant PTSD is gaining attention.

Increased government funding and supportive regulations for mental health services, including PTSD treatment, are promoting the growth of the market. There's also a trend towards policies that ensure better coverage and access to PTSD therapies under health insurance.

Post Traumatic Stress Disorder Market Segmentation

Market Breakup by Treatment Type
  • Drug Administration
  • Psychotherapy
Market Breakup by Drug Class
  • Antidepressants
  • Anti-Anxiety Drugs
  • Antipsychotic Drugs
  • Others
Market Breakup by Patient Type
  • Children
  • Adult
Market Breakup by Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Other Distribution Channels
Market Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
Post Traumatic Stress Disorder (PTSD) Market Overview

In North America, the PTSD market is influenced by a high awareness of mental health issues and robust healthcare infrastructure. The region has a significant number of veterans and active military personnel, leading to focused PTSD research and treatment programs. There's also a growing acceptance of mental health services and an increase in the use of therapy, including cognitive-behavioral therapy and EMDR, coupled with pharmaceutical interventions.

Europe's market is characterized by strong mental health policies and a focus on integrated care. The region benefits from universal healthcare systems, ensuring access to mental health services. There's an emphasis on early intervention and community-based support, with countries like the UK and Germany leading in mental health research and therapy services. The market is also influenced by initiatives aimed at reducing the stigma associated with mental health conditions, including PTSD.

The PTSD market in the Japan region is growing, driven by increasing recognition of mental health issues and improving healthcare infrastructure. Cultural factors and stigma associated with mental health can pose challenges. However, there's a gradual shift towards recognizing and treating PTSD, especially in countries with increasing urbanization and changing social dynamics. The market shows potential for growth in therapy services and pharmaceutical treatments, though access to care varies across the region.

Post Traumatic Stress Disorder (PTSD) Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.
  • Sanofi-aventis Groupe
  • Emergent BioSolutions Inc.
  • Valneva SE
  • GlaxoSmithKline plc.
  • Intervet Inc.
  • EuBiologics Co., Ltd.
  • Astellas Pharma Inc.
  • Celldex Therapeutics.
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Marinus Pharmaceuticals, Inc.
  • Tonix Pharmaceuticals Holding Corp.
  • Greenstone LLC
  • Otsuka Pharmaceutical Co., Ltd
  • Prometheon Pharma, LLC.
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

*Please Note:* The report will take 7 business days to complete, after order confirmation.


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Post Traumatic Stress Disorder (PTSD) Epidemiology Analysis – 7MM
3.1 7MM Epidemiology Scenario Overview (2017-2032)
3.2 United States Post Traumatic Stress Disorder (PTSD) Epidemiology Forecast (2017-2032)
3.3 EU-4 and United Kingdom Post Traumatic Stress Disorder (PTSD) Epidemiology Forecast (2017-2032)
3.3.1 Germany Post Traumatic Stress Disorder (PTSD) Epidemiology Forecast (2017-2032)
3.3.2 France Post Traumatic Stress Disorder (PTSD) Epidemiology Forecast (2017-2032)
3.3.3 Italy Post Traumatic Stress Disorder (PTSD) Epidemiology Forecast (2017-2032)
3.3.4 Spain Post Traumatic Stress Disorder (PTSD) Epidemiology Forecast (2017-2032)
3.3.5 United Kingdom Post Traumatic Stress Disorder (PTSD) Epidemiology Forecast (2017-2032)
3.4 Japan Post Traumatic Stress Disorder (PTSD) Epidemiology Forecast (2017-2032)
4 Post Traumatic Stress Disorder (PTSD) Market Overview – 7MM
4.1 Post Traumatic Stress Disorder (PTSD) Market Historical Value (2017-2023)
4.2 Post Traumatic Stress Disorder (PTSD) Market Forecast Value (2024-2032))
5 Post Traumatic Stress Disorder (PTSD) Market Landscape-7MM
5.1 Post Traumatic Stress Disorder (PTSD) Developers Landscape
5.1.1 Analysis by Year of Establishment
5.1.2 Analysis by Company Size
5.1.3 Analysis by Region
5.2 Post Traumatic Stress Disorder (PTSD) Product Landscape
5.2.1 Analysis by Diseases Type
5.2.2 Analysis by Treatments
5.2.3 Analysis by Route of Administration
6 Post Traumatic Stress Disorder (PTSD) Treatment Challenges and Unmet Needs
6.1 Treatment Pathway Challenges
6.2 Compliance and Drop-Out Analysis
6.3 Awareness and Prevention Gaps
7 Cost of Treatment
8 Post Traumatic Stress Disorder (PTSD) Market Dynamics
8.1 Market Drivers and Constraints
8.2 SWOT Analysis
8.3 Porter’s Five Forces Model
8.4 Key Demand Indicators
8.5 Key Price Indicators
8.6 Industry Events, Initiatives, and Trends
8.7 Value Chain Analysis
9 Post Traumatic Stress Disorder (PTSD) Market Segmentation -7MM
9.1 Post Traumatic Stress Disorder (PTSD) Market by Treatment Type
9.1.1 Market Overview
9.1.2 Drug Administration
9.1.3 Psychotherapy
9.2 Post Traumatic Stress Disorder (PTSD) Market by Drug Class
9.2.1 Market Overview
9.2.2 Antidepressants
9.2.3 Anti-Anxiety Drugs
9.2.4 Antipsychotic Drugs
9.2.5 Others
9.3 Post Traumatic Stress Disorder (PTSD) Market by Patient Type
9.3.1 Market Overview
9.3.2 Children
9.3.3 Adult
9.4 Post Traumatic Stress Disorder (PTSD) Market by Distribution Channel
9.4.1 Market Overview
9.4.2 Hospital Pharmacies
9.4.3 Retail Pharmacies
9.4.4 Other Distribution Channels
9.5 Post Traumatic Stress Disorder (PTSD) Market by Region
9.5.1 Market Overview
9.5.2 United States
9.5.3 EU-4 and the United Kingdom
9.5.3.1 Germany
9.5.3.2 France
9.5.3.3 Italy
9.5.3.4 Spain
9.5.3.5 United Kingdom
9.5.4 Japan
10 United States Post Traumatic Stress Disorder (PTSD) Market
10.1 Post Traumatic Stress Disorder (PTSD) Market Historical Value (2017-2023)
10.2 Post Traumatic Stress Disorder (PTSD) Market Forecast Value (2024-2032)
10.3 Post Traumatic Stress Disorder (PTSD) Market by Disease Type
10.4 Post Traumatic Stress Disorder (PTSD) Market by Treatment Type
11 EU-4 and United Kingdom Post Traumatic Stress Disorder (PTSD) Market
11.1 Post Traumatic Stress Disorder (PTSD) Market Historical Value (2017-2023)
11.2 Post Traumatic Stress Disorder (PTSD) Market Forecast Value (2024-2032)
11.3 Germany Post Traumatic Stress Disorder (PTSD) Market Overview
11.3.1 Post Traumatic Stress Disorder (PTSD) Market by Disease Type
11.3.2 Post Traumatic Stress Disorder (PTSD) Market by Treatment Type
11.4 France Post Traumatic Stress Disorder (PTSD) Market Overview
11.4.1 Post Traumatic Stress Disorder (PTSD) Market by Disease Type
11.4.2 Post Traumatic Stress Disorder (PTSD) Market by Treatment Type
11.5 Italy Post Traumatic Stress Disorder (PTSD) Market Overview
11.5.1 Post Traumatic Stress Disorder (PTSD) Market by Disease Type
11.5.2 Post Traumatic Stress Disorder (PTSD) Market by Treatment Type
11.6 Spain Post Traumatic Stress Disorder (PTSD) Market Overview
11.6.1 Post Traumatic Stress Disorder (PTSD) Market by Disease Type
11.6.2 Post Traumatic Stress Disorder (PTSD) Market by Treatment Type
11.7 United Kingdom Post Traumatic Stress Disorder (PTSD) Market Overview
11.7.1 Post Traumatic Stress Disorder (PTSD) Market by Disease Type
11.7.2 Post Traumatic Stress Disorder (PTSD) Market by Treatment Type
12 Japan Post Traumatic Stress Disorder (PTSD) Market
12.1 Post Traumatic Stress Disorder (PTSD) Market Historical Value (2017-2023)
12.2 Post Traumatic Stress Disorder (PTSD) Market Forecast Value (2024-2032)
12.2.1 Post Traumatic Stress Disorder (PTSD) Market by Disease Type
12.2.2 Post Traumatic Stress Disorder (PTSD) Market by Treatment Type
13 Regulatory Framework
13.1 Regulatory Overview
13.2 US FDA
13.3 EU EMA
13.4 INDIA CDSCO
13.5 JAPAN PMDA
13.6 Others
14 Patent Analysis
14.1 Analysis by Type of Patent
14.2 Analysis by Publication year
14.3 Analysis by Issuing Authority
14.4 Analysis by Patent Age
14.5 Analysis by CPC Analysis
14.6 Analysis by Patent Valuation
14.7 Analysis by Key Players
15 Grants Analysis
15.1 Analysis by year
15.2 Analysis by Amount Awarded
15.3 Analysis by Issuing Authority
15.4 Analysis by Grant Application
15.5 Analysis by Funding Institute
15.6 Analysis by NIH Departments
15.7 Analysis by Recipient Organization
16 Clinical Trials Analysis
16.1 Analysis by Trial Registration Year
16.2 Analysis by Trial Status
16.3 Analysis by Trial Phase
16.4 Analysis by Therapeutic Area
16.5 Analysis by Geography
17 Funding and Investment Analysis
17.1 Analysis by Funding Instances
17.2 Analysis by Type of Funding
17.3 Analysis by Funding Amount
17.4 Analysis by Leading Players
17.5 Analysis by Leading Investors
17.6 Analysis by Geography
18 Partnership and Collaborations Analysis
18.1 Analysis by Partnership Instances
18.2 Analysis by Type of Partnership
18.3 Analysis by Leading Players
18.4 Analysis by Geography
19 Supplier Landscape
19.1 Sanofi-aventis Groupe
19.1.1 Financial Analysis
19.1.2 Product Portfolio
19.1.3 Demographic Reach and Achievements
19.1.4 Mergers and Acquisitions
19.1.5 Certifications
19.2 Emergent BioSolutions Inc.
19.2.1 Financial Analysis
19.2.2 Product Portfolio
19.2.3 Demographic Reach and Achievements
19.2.4 Mergers and Acquisitions
19.2.5 Certifications
19.3 Valneva SE
19.3.1 Financial Analysis
19.3.2 Product Portfolio
19.3.3 Demographic Reach and Achievements
19.3.4 Mergers and Acquisitions
19.3.5 Certifications
19.4 GlaxoSmithKline plc.
19.4.1 Financial Analysis
19.4.2 Product Portfolio
19.4.3 Demographic Reach and Achievements
19.4.4 Mergers and Acquisitions
19.4.5 Certifications
19.5 Intervet Inc.
19.5.1 Financial Analysis
19.5.2 Product Portfolio
19.5.3 Demographic Reach and Achievements
19.5.4 Mergers and Acquisitions
19.5.5 Certifications
19.6 EuBiologics Co., Ltd.
19.6.1 Financial Analysis
19.6.2 Product Portfolio
19.6.3 Demographic Reach and Achievements
19.6.4 Mergers and Acquisitions
19.6.5 Certifications
19.7 Astellas Pharma Inc.
19.7.1 Financial Analysis
19.7.2 Product Portfolio
19.7.3 Demographic Reach and Achievements
19.7.4 Mergers and Acquisitions
19.7.5 Certifications
19.8 Celldex Therapeutics.
19.8.1 Financial Analysis
19.8.2 Product Portfolio
19.8.3 Demographic Reach and Achievements
19.8.4 Mergers and Acquisitions
19.8.5 Certifications
19.9 Johnson & Johnson Services Inc.
19.9.1 Financial Analysis
19.9.2 Product Portfolio
19.9.3 Demographic Reach and Achievements
19.9.4 Mergers and Acquisitions
19.9.5 Certifications
19.10 Merck & Co. Inc.
19.10.1 Financial Analysis
19.10.2 Product Portfolio
19.10.3 Demographic Reach and Achievements
19.10.4 Mergers and Acquisitions
19.10.5 Certifications
19.11 Marinus Pharmaceuticals, Inc.
19.11.1 Financial Analysis
19.11.2 Product Portfolio
19.11.3 Demographic Reach and Achievements
19.11.4 Mergers and Acquisitions
19.11.5 Certifications
19.12 Tonix Pharmaceuticals Holding Corp.
19.12.1 Financial Analysis
19.12.2 Product Portfolio
19.12.3 Demographic Reach and Achievements
19.12.4 Mergers and Acquisitions
19.12.5 Certifications
19.13 Greenstone LLC
19.13.1 Financial Analysis
19.13.2 Product Portfolio
19.13.3 Demographic Reach and Achievements
19.13.4 Mergers and Acquisitions
19.13.5 Certifications
19.14 Otsuka Pharmaceutical Co., Ltd
19.14.1 Financial Analysis
19.14.2 Product Portfolio
19.14.3 Demographic Reach and Achievements
19.14.4 Mergers and Acquisitions
19.14.5 Certifications
19.15 Prometheon Pharma, LLC.
19.15.1 Financial Analysis
19.15.2 Product Portfolio
19.15.3 Demographic Reach and Achievements
19.15.4 Mergers and Acquisitions
19.15.5 Certifications
20 Post Traumatic Stress Disorder (PTSD) - Distribution Model (Additional Insight)
20.1 Overview
20.2 Potential Distributors
20.3 Key Parameters for Distribution Partner Assessment
21 Key Opinion Leaders (KOL) Insights (Additional Insight)
22 Company Competitiveness Analysis (Additional Insight)
22.1 Very Small Companies
22.2 Small Companies
22.3 Mid-Sized Companies
22.4 Large Companies
22.5 Very Large Companies
23 Payment Methods (Additional Insight)
23.1 Government Funded
23.2 Private Insurance
23.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings